Evaluation of Glucocorticoid Sparing Effect in Patients Receiving RoActemra for Rheumatoid Arthritis in Real Life.

Trial Profile

Evaluation of Glucocorticoid Sparing Effect in Patients Receiving RoActemra for Rheumatoid Arthritis in Real Life.

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms SPARE-1
  • Sponsors Roche
  • Most Recent Events

    • 08 Nov 2017 Results of pooled analysis from SPARE-1 and Act-solo studies assessing factors influencing the use of TCZ in Mono or in combination with DMARDs (Combo) in real-life practice in RA patients, were presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 12 Oct 2017 Results (n=884) of pooled analysis from SPARE-1 and Act-solo studies, presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
    • 17 Jun 2017 Results of pooled analysis (n=1494) of three observational studies (PEPS, Spare-1 and Act-solo), presented at the 18th Annual Congress of the European League Against Rheumatism.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top